Roche Hldg Ltd Spons (RHHBY) 36.5400 $RHHBY Novartis'

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 3:41 PM

Roche Hldg Ltd Spons (RHHBY) 36.5400 $RHHBY

Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 08, 11:50AM CDT
Novartis AG (NVS) announced that its heart failure drug Entresto (previously known as LCZ696) has received FDA approval.
ABT: 49.93 (+0.74), JNJ: 99.53 (+1.13), NVS: 103.22 (+3.20)

Premarket Biotech Digest: Arrowhead Initiates Dosing, Vertex Orkambi Approval, Insider Sales
Kanak Kanti De - at Seeking Alpha - Mon Jul 06, 6:28AM CDT

VRTX: 122.95 (+2.06), NVO: 57.68 (+2.91), ISIS: 53.50 (+0.42), ARWR: 6.68 (+0.07), MDCO: 32.73 (-0.24), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), ABBV: 69.23 (+1.26), GSK: 42.45 (+0.65)

The Weekender
Aviate - at Seeking Alpha - Sun Jul 05, 3:57AM CDT
Greece and Europe It is not over-exaggerating to say that all eyes are on Greece this weekend as the Greek people vote in the referendum. Where it was once seen as the most unlikely of outcomes, there now seems to be a real risk of Grexit,...
GREK: 11.26 (+0.95), TI: 13.19 (+0.48), RYAAY: 73.25 (+1.50), APOL: 14.01 (+0.43), BUD: 126.61 (+6.21), EU: 20.54 (-0.08), VOD: 36.46 (+1.07), PSO: 19.11 (+0.56)

FDA clears upstart Theranos' test system
Seeking Alpha - at Seeking Alpha - Thu Jul 02, 3:07PM CDT

ABT: 49.93 (+0.74), AXDX: 24.91 (+0.13), BIO: 147.97 (+1.27), CBMX: 1.69 (+0.08), CPHD: 58.15 (+0.75), QDEL: 22.74 (+0.40), TRIB: 18.05 (+0.17), QGEN: 25.73 (+1.00), CEMI: 4.97 (+0.08)

Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th!
SA Editor Mike Taylor - Seeking Alpha - Thu Jul 02, 3:00PM CDT
A holiday-shortened week still left biotech investors with plenty to chew over. The start of a decade-long collaboration between Celgene ( CELG ) and Juno Therapeutics ( JUNO ) prompted a new wave of enthusiasm for an already well appreciated CAR-T...
CRMD: 3.78 (+0.16), SGYP: 9.13 (+0.49), MNK: 122.44 (+2.18), BIIB: 388.23 (-11.06), OCAT: 5.22 (+0.14), VRX: 232.32 (+8.93), PRGO: 180.86 (+0.85), VRTX: 122.95 (+2.06), GALT: 2.67 (+0.12), IBB: 372.80 (+6.06), MNKD: 5.38 (+0.25), HNT: 69.12 (+2.32), CELG: 118.84 (+1.97), CNC: 72.91 (+2.06), JNJ: 99.53 (+1.13), MDCO: 32.73 (-0.24), GILD: 113.74 (+0.38), GERN: 4.22 (+0.13), JUNO: 52.05 (+1.72), BXLT: 30.85 (+0.79), EXEL: 3.68 (+0.25), NVS: 103.22 (+3.20)

Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 3:00PM CDT
Exelixis Inc.'s (EXEL) announced that the FDA is extending the review period for the new drug application for skin cancer candidate, cobimetinib by three months.
MRK: 57.95 (+0.57), BMY: 69.27 (+1.38), EXEL: 3.68 (+0.25)

Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug?
Long Term Bio - at Seeking Alpha - Thu Jul 02, 2:33PM CDT

AAVL: 16.25 (+0.62), REGN: 526.01 (+16.98)

Why Exelixis, Inc. Shares Slumped Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 01, 5:21PM CDT
What's Happening: Shares in Exelixis slumped by 10% earlier today and closed 7% down after the company reported that the FDA is delaying a decision regarding approval of its cobimetinib, a therapy for BRAF V600 mutation-positive advanced...
EXEL: 3.68 (+0.25)

What Is Beyond Vision-Loss Blockbuster For Regeneron?
at Investor's Business Daily - Wed Jul 01, 3:12PM CDT
As people get older, they are more prone to vision loss from age-related macular degeneration. The severe "wet" version of the condition is the leading cause of blindness in the U.S., afflicting millions of people over 55. It's caused by leaky,...
GILD: 113.74 (+0.38), AMGN: 154.10 (+2.79), SNY: 51.49 (+2.71), REGN: 526.01 (+16.98), CELG: 118.84 (+1.97)

Aeterna Zentaris' Endometrial Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 1:10PM CDT
Aeterna Zentaris Inc. (AEZS) completed patient enrolment in a phase III ZoptEC study on its oncology candidate zoptarelin doxorubicin.
ABT: 49.93 (+0.74), AEZS: 0.24 (+0.01), AAVL: 16.25 (+0.62)

FDA extends PDUFA date for review of cobimetinib NDA; Exelixis off 8%
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 10:08AM CDT

EXEL: 3.68 (+0.25)

Can Hepatitis B Be A Blockbuster Bug?
at Investor's Business Daily - Wed Jul 01, 7:02AM CDT
The new class of hepatitis C drugs, led by Gilead Sciences (GILD) and AbbVie (ABBV), has turned into one of the biggest success stories in biotech history. Yet hepatitis C is one of only five viruses that cause viral hepatitis. Do any of the others...
INO: 7.46 (+0.19), GBIM: 2.55 (-0.01), ISIS: 53.50 (+0.42), ARWR: 6.68 (+0.07), GILD: 113.74 (+0.38), ASMB: 18.55 (+0.67), TKMR: 11.71 (+0.46), ABBV: 69.23 (+1.26), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), NVS: 103.22 (+3.20)

Roche's MS drug passes trial
at Investor's Business Daily - Tue Jun 30, 5:54PM CDT
Genentech, the U.S. biotech arm of Swiss pharma giant Roche (RHHBY), said that its drug candidate ocrelizumab had succeeded in cutting the relapse rate for multiple-sclerosis patients in 2 late-stage trials. The goal of the studies was to show...
PFE: 34.36 (+0.50)

The iShares MSCI Switzerland Capped ETF: A Fund Worth Yodeling About
Accendo Markets - at Seeking Alpha - Tue Jun 30, 4:16PM CDT

SWZ: 11.77 (+0.33), CS: 28.75 (+1.00), UBS: 21.86 (+0.67), EWL: 34.00 (+1.10), FSZ: 41.05 (+1.28), ABB: 20.59 (+0.58), SYT: 83.21 (+2.79)

Deforestation Impacting Pharmaceutical Industry
Global Risk Insights - at Seeking Alpha - Tue Jun 30, 3:07PM CDT
Global rainforests hold unknown treasures for fighting and curing multiple diseases. But whilst the complete destruction of the world’s remaining rainforests looms on the horizon, pharmaceutical companies are only slowly beginning to tap this...
AZN: 66.45 (+1.90), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), XBI: 252.57 (+5.62), IBB: 372.80 (+6.06), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), SNY: 51.49 (+2.71), NVS: 103.22 (+3.20)

Evotec's Partner Roche Provides Initial Update From Phase IIb Trial in Alzheimer's Disease
GlobeNewswire - Tue Jun 30, 2:27PM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN

E0005664809) was updated today by its partner Roche (SIX:RO) (SIX:ROG) (OTCQX:RHHBY) on the initial results of the Phase IIb trial with Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer's disease ("AD"

. In this study, Sembragiline failed to demonstrate benefit on the primary endpoint (Alzheimer's Disease Assessment Scale - Cognitive Behaviour Subscale, ADAS-cog-11) after 52 weeks of treatment. Preliminary safety analyses showed that Sembragiline was well tolerated with no safety signals identified. Roche has initiated a process to evaluate all secondary endpoint read-outs on Sembragiline and to consider all further development options. The multicentre, randomised, double-blind, parallel-group, placebo-controlled Phase IIb study was undertaken to evaluate the efficacy and safety of Sembragiline in patients with moderate severity Alzheimer's disease added on background of AD standard therapy.
EVT: 20.20 (+0.20), ROG: 58.92 (-1.67)

Roche 'High Efficacy' MS Drug Succeeds In Trials
at Investor's Business Daily - Tue Jun 30, 9:42AM CDT
Genentech, the U.S. biotech arm of Swiss pharma giant Roche (RHHBY), announced Tuesday that its drug candidate ocrelizumab had succeeded in cutting the relapse rate for multiple-sclerosis patients in two late-stage trials. The goal of the studies was...
BIIB: 388.23 (-11.06), PFE: 34.36 (+0.50), SNY: 51.49 (+2.71), NVS: 103.22 (+3.20)

Roche's Multiple Sclerosis Studies Meet Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 30, 8:10AM CDT
Roche Holding AG (RHHBY) announced that two phase III studies on multiple sclerosis candidate ocrelizumab met their primary and major secondary endpoints.
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50)

Genentech's ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Business Wire - Tue Jun 30, 12:00AM CDT
--Genentech will submit data to the U.S. Food and Drug Administration

Roche's Perjeta Recommended for Pre-Surgery Breast Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 29, 3:30PM CDT
Roche's (RHHBY) Perjeta has been recommended by the CHMP as a neoadjuvant treatment of HER2-positive early-stage breast cancer patients.
ABT: 49.93 (+0.74), NVO: 57.68 (+2.91)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Medicare Payment Proposal Faces Doctor Backlash in D.C.

Why Same-Day Medicare Care Matters Imagine you're gasping for breath, struggling to find relief, and then being told to wait weeks for care. It's not just an inconvenience; it's a health hazard. This isn't some arbitrary tale—it's the gritty reality for folks relying on same-day care. A group of docs and advocates recently stormed Capitol Hill sounding the alarm about a...

Crucial Insights for South GA Home Insurance Choices

Understanding the Insurance Jargon Here we go again, dealing with insurance gobbledygook that’s about as clear as mud to most of us. Homeowners in South Georgia are being urged to pay attention to the differences between replacement cost and actual cash value in their insurance policies. This ain't just legalese, folks—it's your protection when disaster strikes in our...

MiniCo's New Desk: A Game Changer for E&S Market

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Local Expertise in Real Estate: Key to Success?

Local Market Know-How: A Seller's Best Asset So you're thinking about selling your home in North Carolina, huh? Here's a tip—get yourself a local real estate pro who knows the ins and outs of your neighborhood like the back of their hand. Michael McCollum, a prominent voice from Reidsville, NC, highlights how crucial local expertise can be in navigating the widely...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

University of Phoenix Grads Shine in Job Readiness

University of Phoenix Graduates Proving Their Worth Dive straight into the world of University of Phoenix grads, and you're looking at some folks who seem to have the workplace game figured out. A fresh Harris Poll, done on behalf of the University itself, paints a rosy picture of these graduates from the eyes of those who actually supervise them. Turns out, managers are...

Vortex Expands UK Reach with Torrent Acquisition Boost

Vortex's Ambitious UK Expansion A seasoned investor keen on infrastructure plays would find Vortex Companies’ latest move significant—not just another acquisition, but a realigned strategy for dominance as Britain braces for an infrastructure overhaul. With Torrent Drainage Services in their pocket, the Vortex Group plans to amp up its trenchless rehabilitation...

Managed Connectivity: Key to Modern Multifamily Living

Connectivity Runs the Modern Show Imagine moving into a shiny new apartment, where the biggest hassle isn't unpacking boxes but ensuring your gadgets get online smoothly. That's the reality of today's multifamily living, where the internet is more than a utility—it's the backbone of modern life. And if you think it's just about offering internet access, you're missing...

Ultrabench Revolutionizes AI Model Comparison Game

Breaking Down the Messy AI Model Landscape Ultrabench.ai is here to drag AI model comparison out of the dark ages. Picture this: 309 AI models, ranked against a whopping 530 benchmarks, all served up on one plate. If you’re navigating the AI jungle, you’ll realize how Ultrabench is no small fish in this vast ocean. Consolidating Where Others Have Scattered There's a...

Li-Fire Expands Fire Safety Amid Rising Battery Risks

A Crunchy Look at New Fire Safety Moves Well, folks, here's a twist we didn't see coming but sure makes sense in today's electrifying business landscape. Li-Fire, the big brains behind lithium battery fire suppression, is spreading its wings nationwide, or at least its wholesale and distribution programs are. And right ahead of National Fire Safety Week no less—talk...